BiVictriX Therapeutics PLC BiVictriX AIM Rule 17 Notice (1999J)
25 April 2022 - 6:30PM
UK Regulatory
TIDMBVX
RNS Number : 1999J
BiVictriX Therapeutics PLC
25 April 2022
BIVICTRIX THERAPEUTICS PLC
("BiVictriX" or "the Company" or "the Group")
AIM Rule 17 Notice
Alderley Park, 25 April 2022 - BiVictriX Therapeutics plc (AIM:
BVX), an emerging biotechnology company applying a novel approach
to develop next generation cancer therapies using insights derived
from frontline clinical experience, announces that Iain Ross,
Chairman of BiVictriX, has advised the Company that further to the
announcement of 17 December 2021 regarding Palla Pharma Limited
("Palla Pharma"), of which he was a Non-Executive Director,
entering into voluntary administration, Palla Pharma has entered
into liquidation. Iain Ross's resignation from the board of Palla
Pharma was accepted on 20 April 2022.
This announcement is made pursuant to Rule 17 and schedule 2,
paragraph (g) of the AIM Rules for Companies.
-Ends-
For more information, please contact:
BiVictriX Therapeutics plc
Tiffany Thorn, Chief Executive Officer
Iain Ross, Chairman Email: info@bivictrix.com
SP Angel Corporate Finance LLP (NOMAD Tel: +44 (0) 20 3470 0470
and Broker)
David Hignell, Caroline Rowe (Corporate
Finance)
Vadim Alexandre, Rob Rees (Sales and
Broking) Tel: +44 (0) 20 7886 2500
Panmure Gordon (UK) Limited (Joint Broker)
Rupert Dearden, Freddy Crossley, Emma
Earl
Consilium Strategic Communications
Mary-Jane Elliott, Melissa Gardiner, Tel: +44 (0) 20 3709 5700
Genevieve Wilson Email: Bivictrix@consilium-comms.com
About BiVictriX Therapeutics plc
BiVictriX is a UK-based drug discovery and development company
which is focused on leveraging clinical experience to develop a
class of highly selective, next generation cancer therapeutics
which exhibit superior potency, whilst eliminating
treatment-related toxicities.
The Company utilises a first-in-class approach to generate a
proprietary pipeline of Bi-Cygni(R) therapeutics which are designed
to selectively target antigen co-expression fingerprints, or "twin
antigens", on tumour cells, which are largely absent from healthy
cells. Whereas this concept has been validated in a clinical
diagnostic setting to support the diagnosis and monitoring of
haematological cancers, it has not yet been widely used in a
therapeutic setting.
BiVictriX has identified a diverse panel of novel
cancer-specific "twin antigens", across a broad range of solid
tumour and haematological cancer indications. The Company is using
these novel "twin-antigens" to develop more effective and safer
therapeutics to target cancers that are expected to constitute
orphan indications and currently constitute areas of high unmet
medical need.
Find out more about BiVictriX online at www.bivictrix.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCPPUMPCUPPURA
(END) Dow Jones Newswires
April 25, 2022 04:30 ET (08:30 GMT)
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From Apr 2024 to May 2024
Bivictrix Therapeutics (LSE:BVX)
Historical Stock Chart
From May 2023 to May 2024